WO2022003439A1 - Therapeutic agents for treating and preventing autoimmune diseases and cancer and a screening method - Google Patents
Therapeutic agents for treating and preventing autoimmune diseases and cancer and a screening method Download PDFInfo
- Publication number
- WO2022003439A1 WO2022003439A1 PCT/IB2021/054450 IB2021054450W WO2022003439A1 WO 2022003439 A1 WO2022003439 A1 WO 2022003439A1 IB 2021054450 W IB2021054450 W IB 2021054450W WO 2022003439 A1 WO2022003439 A1 WO 2022003439A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- poe
- arid5a
- cells
- cancer
- inhibitor
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 31
- 201000011510 cancer Diseases 0.000 title claims abstract description 29
- 208000023275 Autoimmune disease Diseases 0.000 title claims abstract description 28
- 238000000034 method Methods 0.000 title claims abstract description 24
- 238000012216 screening Methods 0.000 title abstract description 7
- 239000003814 drug Substances 0.000 title description 14
- 229940124597 therapeutic agent Drugs 0.000 title description 8
- 239000003112 inhibitor Substances 0.000 claims abstract description 65
- 230000005764 inhibitory process Effects 0.000 claims abstract description 5
- 201000006417 multiple sclerosis Diseases 0.000 claims description 17
- 201000004681 Psoriasis Diseases 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 9
- 206010006187 Breast cancer Diseases 0.000 claims description 8
- 208000026310 Breast neoplasm Diseases 0.000 claims description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 8
- 206010060862 Prostate cancer Diseases 0.000 claims description 8
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 8
- 201000005202 lung cancer Diseases 0.000 claims description 8
- 208000020816 lung neoplasm Diseases 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 7
- 208000037976 chronic inflammation Diseases 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 230000006020 chronic inflammation Effects 0.000 claims description 5
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 230000009702 cancer cell proliferation Effects 0.000 claims 1
- 230000027455 binding Effects 0.000 abstract description 13
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 13
- 239000003937 drug carrier Substances 0.000 abstract description 8
- 238000003670 luciferase enzyme activity assay Methods 0.000 abstract description 7
- 238000000338 in vitro Methods 0.000 abstract description 6
- 238000000126 in silico method Methods 0.000 abstract description 4
- 238000000159 protein binding assay Methods 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 43
- 230000000694 effects Effects 0.000 description 26
- 108020004999 messenger RNA Proteins 0.000 description 26
- 238000011282 treatment Methods 0.000 description 26
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 23
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 23
- 210000001744 T-lymphocyte Anatomy 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 21
- 230000006870 function Effects 0.000 description 19
- 239000000203 mixture Substances 0.000 description 19
- 210000000068 Th17 cell Anatomy 0.000 description 17
- 201000002491 encephalomyelitis Diseases 0.000 description 17
- 230000000087 stabilizing effect Effects 0.000 description 17
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- 239000013612 plasmid Substances 0.000 description 13
- 102000004889 Interleukin-6 Human genes 0.000 description 12
- 108090001005 Interleukin-6 Proteins 0.000 description 12
- 230000035772 mutation Effects 0.000 description 12
- 101150099493 STAT3 gene Proteins 0.000 description 11
- 229940100601 interleukin-6 Drugs 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 108020005345 3' Untranslated Regions Proteins 0.000 description 10
- 208000009386 Experimental Arthritis Diseases 0.000 description 10
- 230000000770 proinflammatory effect Effects 0.000 description 10
- 102000004127 Cytokines Human genes 0.000 description 9
- 108090000695 Cytokines Proteins 0.000 description 9
- 101150101999 IL6 gene Proteins 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 9
- 238000006467 substitution reaction Methods 0.000 description 9
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 8
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 7
- 108060001084 Luciferase Proteins 0.000 description 7
- 239000005089 Luciferase Substances 0.000 description 7
- 239000002285 corn oil Substances 0.000 description 7
- 235000005687 corn oil Nutrition 0.000 description 7
- 239000002158 endotoxin Substances 0.000 description 7
- 229920006008 lipopolysaccharide Polymers 0.000 description 7
- 210000002540 macrophage Anatomy 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 101100297347 Caenorhabditis elegans pgl-3 gene Proteins 0.000 description 6
- 102000013691 Interleukin-17 Human genes 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 210000003169 central nervous system Anatomy 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 239000012228 culture supernatant Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 206010015150 Erythema Diseases 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 231100000321 erythema Toxicity 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 206010030113 Oedema Diseases 0.000 description 4
- 230000001028 anti-proliverative effect Effects 0.000 description 4
- -1 but not limited to Substances 0.000 description 4
- 239000013592 cell lysate Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000004088 simulation Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 101100447432 Danio rerio gapdh-2 gene Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 101150112014 Gapdh gene Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000001363 autoimmune Effects 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 230000001712 encephalitogenic effect Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000002452 interceptive effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000003032 molecular docking Methods 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 210000005212 secondary lymphoid organ Anatomy 0.000 description 3
- 229940099259 vaseline Drugs 0.000 description 3
- YDIOFXQRVLYTMT-UHFFFAOYSA-N 1-phenyl-2-[(5-pyridin-4-yl-1,3,4-oxadiazol-2-yl)sulfanyl]ethanone Chemical compound C=1C=CC=CC=1C(=O)CSC(O1)=NN=C1C1=CC=NC=C1 YDIOFXQRVLYTMT-UHFFFAOYSA-N 0.000 description 2
- 101710159080 Aconitate hydratase A Proteins 0.000 description 2
- 101710159078 Aconitate hydratase B Proteins 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 108090000467 Interferon-beta Proteins 0.000 description 2
- 102100033467 L-selectin Human genes 0.000 description 2
- 101100323954 Mus musculus Arid5a gene Proteins 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 2
- 230000004570 RNA-binding Effects 0.000 description 2
- 101710105008 RNA-binding protein Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229960000548 alemtuzumab Drugs 0.000 description 2
- 210000003423 ankle Anatomy 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000003633 gene expression assay Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 230000024949 interleukin-17 production Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- 229960005027 natalizumab Drugs 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 210000003024 peritoneal macrophage Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 208000005440 Basal Cell Neoplasms Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 206010022004 Influenza like illness Diseases 0.000 description 1
- 102100026720 Interferon beta Human genes 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101001076414 Mus musculus Interleukin-6 Proteins 0.000 description 1
- 241001049988 Mycobacterium tuberculosis H37Ra Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010081690 Pertussis Toxin Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000242739 Renilla Species 0.000 description 1
- 102000004495 STAT3 Transcription Factor Human genes 0.000 description 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000005441 aurora Substances 0.000 description 1
- 229940090047 auto-injector Drugs 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000012405 in silico analysis Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 230000017306 interleukin-6 production Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000010212 intracellular staining Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 1
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 150000004866 oxadiazoles Chemical class 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001137 tarsal bone Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
Definitions
- RNA-binding protein (RBP) inhibitors relate to RNA-binding protein (RBP) inhibitors, and particularly, to Arid5a inhibitors, methods of screening for Arid5a inhibitors, and methods of treating autoimmune diseases and cancer using an Arid5a inhibitor.
- RBP RNA-binding protein
- Inflammation a body response to an injury, is divided into acute and chronic inflammation, wherein the chronic inflammation is a long-lasting event usually over months and years.
- Autoimmune diseases are chronic inflammatory diseases caused when a subject’s own immune system attacks otherwise healthy cells in the body.
- Common autoimmune diseases include multiple sclerosis (MS), rheumatoid arthritis (RA), psoriasis, inflammatory bowel disease (IBD), lupus, type 1 diabetes, Graves’ disease, and Guillan-Barre syndrome.
- Common symptoms of autoimmune diseases include fatigue, joint pain and swelling, skin problems, abdominal pain or digestive issues, recurring fever, swollen glands, and metabolic issues.
- Current treatments for autoimmune diseases are focused on alleviating symptoms and include primarily non-steroidal anti-inflammatory drugs (NSAIDs) and drugs intended to suppress the immune response.
- NSAIDs non-steroidal anti-inflammatory drugs
- autoimmune disease for example, neuron in MS, joints in RA and the skin in psoriasis
- cytokines and mediators pro-inflammatory cytokines and mediators.
- MS as a representative of autoimmune diseases, involves both the innate and adaptive immune responses.
- Innate immune cells such as macrophages, contribute to pathogenesis of MS by secretion of pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor- ⁇ (TNF- ⁇ ).
- pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor- ⁇ (TNF- ⁇ ).
- IL-6 interleukin-6
- TNF- ⁇ tumor necrosis factor- ⁇
- APCs antigen-presenting cells
- These differentiated cells mainly IL-17-secreting T helper 17 (Th17) cells are implicated in MS pathogenesis. Therefore, reducing any or all of the above mentioned pro- inflammatory cytokines, which are greatly implicated in autoimmune inflammation, has been an area of active investigation to develop a therapeutic strategy to treat MS.
- DMT disease-modifying treatments
- IFN- ⁇ interferon- ⁇
- Other therapeutic agents such as mitoxantrone and humanized antibodies including daclizumab, natalizumab and alemtuzumab exert promising therapeutic effects in MS patients.
- Mitoxantrone is associated with cardiotoxicity and acute leukemia
- alemtuzumab is associated with autoimmune-associated complications
- natalizumab is associated with progressive multifocal leukoencephalopathy.
- Cancer is a disease caused by dysregulation of the cell division cycle, resulting in an uncontrolled growth of cells. Cancers are categorized based upon the cell type from which the cancer originated. Common cancers include breast cancer, prostate cancer, basal cell cancer, melanoma, colon cancer, lung cancer, leukemia, and lymphoma. Generally, cancer treatments focus on killing rapidly dividing cells. Common treatments include radiation therapies and chemotherapies. More recent treatments have been able to target some specific types of cancer cells. Flowever, most cancer treatments have significant side effects and are not always well tolerated.
- Therapeutic agents for treating and preventing autoimmune diseases and cancer can include compositions comprising an AT-rich interactive domain containing 5 a (Arid5a) inhibitor.
- the autoimmune diseases can include diseases associated with chronic inflammation.
- the autoimmune diseases can include but are not limited to, multiple sclerosis, rheumatoid arthritis, and psoriasis.
- the cancer may include but is not limited to, breast cancer, prostate cancer, and lung cancer.
- the Arid5a inhibitor can inhibit the RNA-binding activities of Arid5a and the subsequent stabilizing functions on target mRNAs encoding pro- inflammatory mediators.
- the Arid5a inhibitor can include 1-Phenyl-2-(5-pyridin-4-yl- [1,3,4]oxadiazol-2-ylsulfanyl)-ethanone (herein, “POE”), having a chemical structure according to the formula: or a pharmaceutically acceptable salt thereof. It should be understood that the Arid5a inhibitor POE includes analogs of POE having any dihedral angles.
- the Arid5a inhibitors may include POE analogs having a chemical structure according to the following general formula: wherein each of R 1 and R 2 is independently selected from H, alkyl, phenyl, substituted phenyl, a 5-membered heteroaryl, and 6-membered heteroaryl; each of X and Y is independently selected from S, O, and NH; and n is an integer representing a number of Cs selected from 0, 1, and 2. Preferably, n is 1.
- the POE analogs include but are not limited to:
- the POE analog is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-oxide
- the POE analog is POE A3.
- POE analogs POE A1, POE A2 and POE A3 are shown for illustrations purposes only, and the Arid5a inhibitors include POE analogs having the chemical structure according to the general formula.
- a method for treating and preventing autoimmune diseases and cancer can include administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising one or more (Arid5a) inhibitors alone or combined with other therapeutic or prophylactic agents.
- Fig. 1A depicts a graph of the effects of POE on Arid5a-mediated stability of the OX403’UTR.
- Fig. IB depicts a graph of the effects of POE on Arid5a- mediated stability of the Il63’UTR.
- Fig. 1C depicts a graph of the effects of POE on Arid5a- mediated stability of the
- FIG. 2A depicts a graph of the effect of substitution mutations in Arid5a on POE- mediated inhibition of Arid5a stabilizing function on the OX403’UTR.
- Fig. 2B depicts a graph of the effect of substitution mutations in Arid5a on POE- mediated inhibition of Arid5a stabilizing function on the Il63’UTR.
- Fig. 2C depicts a graph of the effect of substitution mutations in Arid5a on POE- mediated inhibition of Arid5a stabilizing function on the Stat33’UTR.
- Fig. 3A depicts a graph of the effects of POE on IL-6 production by macrophages.
- Fig. 3B depicts a graph of the effects of POE on TNF- ⁇ production by macrophages.
- Fig. 3C depicts a graph of the effects of POE on IL-17 production by differentiated Th17 cells.
- Fig. 3D depicts a graph of the effects of POE on CD4 + OX40 + T cells in differentiated Th17 cells.
- Fig. 3E depicts a graph of the effect of POE on Stat3 mRNA expression in differentiated Th17 cells.
- Fig. 4 depicts the effect of POE on Arid5a binding to the alternative decay element (ADE)-like stem loop in the OX403'UTR.
- ADE alternative decay element
- Fig. 5A depicts a graph of EAE score over time with and without POE treatment.
- Fig. 5B depicts a graph of IL-6 and TNF- ⁇ serum levels in the EAE model with and without treatment with POE.
- Fig. 5C depicts a graph of IL-17 production by encephalitogenic CD4 + T cells in response to restimulation in the EAE model with and without treatment with POE.
- Fig. 5D depicts a graph of OX40 mRNA levels in CD4 + T cells isolated from the CNS in the EAE model with and without treatment with POE.
- Fig. 5E depicts a graph of percentage of CD4 + OX40 + T cells isolated from the CNS in EAE model with and without treatment with POE.
- Fig. 6 depicts a graph of the efficient inhibitory effects of POE and its example analogs POE A1-A3 on Arid5a stabilizing function on Il63’UTR through the target domain of Arid5a.
- Fig. 7A depicts a graph of CIA clinical score over time with and without treatment with POE or its example analogs POE A1 or POE A2.
- Fig. 7B depicts a graph of IL-6 serum level in the CIA model with and without treatment with POE or its example analogs POE A1 or POE A2.
- Fig. 7C depicts a graph of the percentage of CD4 + IL-17 + T cells in secondary lymphoid organs in the CIA model with and without treatment using POE or its example analogs POE A1 or POE A2.
- Fig. 8A depicts a graph of the score of IMQ-induced-psoriasis model over time with and without treatment with POE or its example analogs POE A2 or POE A3.
- Fig. 8B depicts a graph of mRNA expression of Il6 and II17a in a biopsy from IMQ-induced-psoriasis model with and without treatment with POE or its example analogs POE A2 or POE A3.
- Fig. 9A depicts a graph of the anti-proliferative effects of POE and its example analogs POE A1-A3 on MDA-MB-231 breast cancer cells.
- Fig. 9B depicts a graph of the anti-proliferative effects of POE and its example analogs POE A1-A3 on LNCaP prostate cancer cells.
- Fig. 9C depicts a graph of the anti-proliferative effects of POE and its example analogs POE A1-A3 on A549 lung cancer cells.
- a “subject” includes mammals, e.g., humans, dogs, cats, sheep, cows, rats, mice, and the like.
- Arid5a refers to AT -rich interactive domain-containing 5a (Arid5A), a protein that stabilizes mRNAs encoding pro-inflammatory mediators, including signal transducer and activator of transcription 3 ( Stat3 ), Il6, and OX40 (CD 134).
- an effective amount refers to an amount which provides a therapeutic or prophylactic benefit.
- therapeutic agents for treating and preventing autoimmune diseases and cancer can include compositions comprising an AT-rich interactive domain containing 5a (Arid5a) inhibitor.
- the autoimmune diseases can include diseases associated with chronic inflammation.
- the autoimmune diseases can include but are not limited to, multiple sclerosis, rheumatoid arthritis, and psoriasis.
- the cancer may include but is not limited to, breast cancer, prostate cancer, and lung cancer.
- the Arid5a inhibitor can inhibit the RNA-binding activities of Arid5a and the subsequent stabilizing functions on target mRNAs encoding pro-inflammatory mediators.
- the Arid5a inhibitor can include 1- Phenyl -2-(5-pyridin-4-yl-[ 1 ,3,4]oxadiazol-2-ylsulfanyl)-ethanone (herein, “POE”), having a chemical structure according to the formula: or a pharmaceutically acceptable salt thereof. It should be understood that the Arid5a inhibitor POE includes analogs of POE having any dihedral angles.
- the Arid5a inhibitors include POE analogs having a chemical structure according to the following general formula: wherein each of R 1 and R 2 is independently selected from H, alkyl, phenyl, substituted phenyl, a 5-membered heteroaryl, and 6-membered heteroaryl; each of X and Y is independently selected from S, O, and NH; and n is an integer representing a number of Cs selected from 0, 1, and 2. Preferably, n is 1.
- a method for treating and preventing autoimmune diseases and cancer can include administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising one or more (Arid5a) inhibitors alone or combined with other therapeutic or prophylactic agents.
- Arid5a is required for pathogenesis of experimental autoimmune encephalomyelitis (EAE), a murine model of MS, by stabilizing the mRNAs of Il6 and OX40. Arid5a is also required for autoimmunity through promoting differentiation and effector functions of Th17 cells by stabilizing Stat3 and OX40 mRNAs. Accordingly, the Arid5a inhibitor can be administered to a subject to treat autoimmune diseases, including but not limited to MS, RA, and Psoriasis.
- EAE experimental autoimmune encephalomyelitis
- the Arid5a inhibitor can be used to prevent the proliferation of cancer cells.
- Arid5a inhibitors are herein shown to inhibit proliferation of a broad spectrum of cancer cells including breast cancer cells, lung cancer cells, and prostate cancer cells. Accordingly, in an embodiment the Arid5a inhibitor may be administered to a subject in need thereof to prevent the proliferation of cancer cells.
- the cancer cells including but not limited to breast cancer cells, lung cancer cells, or prostate cancer cells.
- An embodiment of the present subject matter is directed to a pharmaceutical composition
- a pharmaceutical composition comprising the Arid5a inhibitor compound and a pharmaceutically acceptable carrier.
- the pharmaceutical composition includes the Arid5a inhibitor compound in combination with at least one of a therapeutic agent and a prophylactic agent.
- An embodiment of the present subject matter is directed to a method of making the pharmaceutical composition including mixing the Arid5a inhibitor with a pharmaceutically acceptable carrier.
- the method of making the pharmaceutical composition can include mixing the Arid5a inhibitor under sterile conditions with a pharmaceutically acceptable carrier and preservatives, buffers, or propellants to create the pharmaceutical composition; and presenting the pharmaceutical composition in a form suitable for daily, weekly, monthly, or life-long administration.
- An embodiment of the present subject matter is directed to an analog or derivative of the Arid5a inhibitors described herein.
- the Arid5a inhibitors described herein are candidates for derivatization.
- analogs of the Arid5a inhibitors described herein that have modulated potency, selectivity, and solubility are included herein and provide useful leads for drug discovery and drug development.
- new analogs are designed considering issues of drug delivery, metabolism, novelty, and safety.
- composition of the present subject matter may be administered orally, nasally, rectally, parenterally, intracisternally, intra vaginally, intraperitoneally, topically, transdermally, by surgical implantation, or by intravenous or intramuscular injections.
- composition of the present subject matter is administered in a form selected from liquid oral preparations, solid oral preparations, parenteral preparations, injectable suspensions, and liposomes.
- the Arid5a inhibitors or pharmaceutical compositions can be administered to a subject by any suitable route.
- the compositions can be administered orally (including bucally and sublingually), nasally, rectally, intracisternally, intra vaginally, intraperitoneally, topically, transdermally (as by powders, ointments, or drops), parenterally, and/or by surgical implantation.
- parenteral administration refers to modes of administration other than through the gastrointestinal tract, which include intravenous, intramuscular, intraperitoneal, intrasternal, intramammary, intraocular, retrobulbar, intrapulmonary, intrathecal, subcutaneous and intraarticular injection and infusion.
- Surgical implantation may also be contemplated, including, for example, embedding the composition in the body such as, for example, in a tissue, in the abdominal cavity, under the splenic capsule, brain, or in the cornea.
- the route of administration can include intranasal administration, oral administration, inhalation administration, subcutaneous administration, transdermal administration, intradermal administration, intra-arterial administration with or without occlusion, intracranial administration, intraventricular administration, intravenous administration, buccal administration, intraperitoneal administration, intraocular administration, intramuscular administration, implantation administration, topical administration, intratumor administration, and/or central venous administration.
- the Arid5a inhibitors or a salt thereof, as the active ingredient is intimately admixed with a pharmaceutically acceptable carrier according to conventional pharmaceutical compounding techniques.
- Carriers are inert pharmaceutical excipients, including, but not limited to, binders, suspending agents, lubricants, flavorings, sweeteners, preservatives, dyes, and coatings.
- any of the pharmaceutical carriers known in the art may be employed.
- suitable carriers and additives include water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, and the like.
- suitable carriers and additives include starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like.
- the carrier will usually comprise sterile water, though other ingredients, for example, for purposes such as aiding solubility or for preservation, may be included. Injectable suspensions may also be prepared, in which case appropriate liquid carriers, suspending agents, and the like may be employed.
- the pharmaceutically acceptable carrier can include alcohol, dimethyl sulfoxide (DMSO), a physiological saline, a lipid based formulation, a liposomal formulation, a nanoparticle formulation, a micellar formulation, a water soluble formulation, a biodegradable polymer, an aqueous preparation, a hydrophobic preparation, a lipid based vehicle, or a polymer formulation.
- the Arid5a inhibitors of the present disclosure also can be administered in the form of liposomes.
- Liposomes generally are derived from phospholipids or other lipid substances and are formed by mono- or multi-lamellar hydrated liquid crystals dispersed in an aqueous medium. Any nontoxic, physiologically acceptable and metabolizable lipid capable of forming liposomes can be used.
- the present compositions in liposome form can include, in addition to a compound of the present disclosure, stabilizers, preservatives, excipients, and the like.
- the preferred lipids are the phospholipids and the phosphatidyl cholines (lecithins), both natural and synthetic.
- compositions for parenteral injection can include pharmaceutically acceptable sterile aqueous or non-aqueous solutions, dispersions, suspensions, or emulsions, as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to use.
- suitable aqueous and nonaqueous carriers, diluents, solvents, or vehicles include water ethanol, polyols (such as, glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils (such, as olive oil), and injectable organic esters such as ethyl oleate.
- Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
- compositions can include adjuvants such as preservatives, wetting agents, emulsifying agents, and dispersing agents. Prevention of the action of microorganisms can be ensured by the inclusion of various anti-bacterial and anti-fungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It also may be desirable to include isotonic agents such as sugars, sodium chloride, and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the inclusion of agents which delay absorption, such as aluminum monostearate and gelatin. In some cases, in order to prolong the effect of the drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection.
- adjuvants such as preservatives, wetting agents, emulsifying agents, and dispersing agents.
- Prevention of the action of microorganisms can be ensured by the inclusion of various anti-bacterial and anti-fungal agents, for example, paraben, chlorobutanol
- compositions can be in unit dosage forms such as tablets, pills, capsules, powders, granules, ointments, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampules, auto-injector devices or suppositories, for oral parenteral, intranasal, sublingual or rectal administration, or for administration by inhalation or insufflation.
- the active compound can be mixed under sterile conditions with a pharmaceutically acceptable carrier and, if required, any needed preservatives, buffers, or propellants.
- the composition can be presented in a form suitable for daily, weekly, monthly, or life-long administration.
- compositions herein will contain, per dosage unit, e.g., tablet, capsule, powder, injection, teaspoonful, suppository and the like, an amount of the active ingredient necessary to deliver an effective dose.
- a therapeutically effective amount of the Arid5a inhibitor or an amount effective to treat an autoimmune disease or cancer may be determined initially from the Examples described herein and adjusted for a specific desired Arid5a inhibitor using routine methods.
- a therapeutically effective amount is an amount sufficient to achieve the desired therapeutic effects, e.g., a concentration of Arid5a inhibitor in plasma that ranges from about 1 nM to about 25 uM.
- the present subject matter includes a method of identifying candidate Arid5a inhibitors.
- An in silico analysis may be conducted to screen for candidate inhibitors.
- molecular docking simulations can be used for screening a candidate inhibitor useful for treating autoimmune diseases and cancer.
- Candidate Arid5a inhibitors may be selected based on predicted interactions with a target domain in Arid5a.
- the target domain may be Pocket X, a feature of the Arid5a protein including, but not limited to, amino acids Glu53, Phe56, Leu57, VaI58, Leu84, Tyr88, Leul33, VaI134, Tyrl37, VaI138, Hisl40, and Leul41.
- Candidate Arid5a inhibitors are then tested in vitro by examining the candidate inhibitors’ effects on the stabilizing function of Arid5a on target mRNAs encoding pro- inflammatory mediators using a luciferase assay.
- the mRNAs can be of OX40, Il6, and Stat3.
- Candidate Arid5a inhibitors are then tested in vitro by examining the candidate inhibitors’ effects on Arid5a binding activities to stem loops in the 3’UTR of target mRNAs and production of pro-inflammatory mediators using a RNA-protein binding system, PCR, and ELISA tests.
- the therapeutic potential of candidate Arid5a inhibitors may be assessed in vivo using commonly used representative experimental autoimmune models including MS, RA and psoriasis.
- a therapeutic potential can be determined according to clinical scores, cytokine levels, changes in CD4 + T cell population, and OX40 expression.
- mice Female C57BL/6 mice (6-8 weeks) were purchased originally from Charles River and maintained under specific pathogen-free conditions. All in vivo and in vitro animal experiments were performed using these mice at Laboratory of Physiology and Immunology, King Faisal University, Saudi Arabia, in accordance with institutional guidelines.
- the peritoneal macrophages were stimulated in vitro with 0.5 ⁇ g/mL lipopolysaccharides (LPS) (Sigma- Aldrich) for 24 h.
- LPS lipopolysaccharides
- the CD4 + CD62L + T cells were isolated and purified from spleen using the MACS isolation kit (Miltenyi).
- the T cells were cultured in the presence of anti-CD3/CD28 dynabeads (Invitrogen), recombinant mouse IL-6 (30 ng/mL; R&D Systems), recombinant transforming growth factor- ⁇ (TGF- ⁇ ) (4 ng/mL; R&D Systems), anti-interferon- ⁇ (IFN- ⁇ ) and anti-IL-4 (10 ⁇ g/mL; Biolegend) for 72 h to generate Th17 cells.
- anti-CD3/CD28 dynabeads Invitrogen
- recombinant mouse IL-6 (30 ng/mL; R&D Systems
- TGF- ⁇ recombinant transforming growth factor- ⁇
- IFN- ⁇ anti-interferon- ⁇
- anti-IL-4 10 ⁇ g/mL; Biolegend
- the mRNAs and cytokines were quantified as follows. A first strand of cDNA was synthesized from total RNA by using the TaqMan reverse transcription kit. The cDNA was amplified in the real-time PCR system ViiA7 using TaqMan gene expression assays of OX40 (Mm01261022_ml), Stat3 (Mm01219775_ml) and the endogenous control Gapdh (Mm99999915_gl). Kits, probes and reagents were from Applied Biosystems. The relative expression of mRNAs was calculated by AACt method. For cytokines quantification in serum and cell culture supernatants, ELISA kits of IL-17a, IL-6, TNF- ⁇ (Invitrogen) were used following the manufacturer’s instructions.
- Flow cytometry analysis was conducted using CD4 + T cells cultured under Th17 cell-inducing conditions or CD4 + T cells derived from CNS, which were fixed and stained with Per-CP-Cy5.5-conjugated anti-CD4 antibodies and PE-conjugated anti-OX40 antibodies (Biolegend). Analysis was carried out using Flowsight (Amnis).
- Arid5a inhibitor POE The potential interaction between Arid5a inhibitor POE and Arid5a was predicted by in silico modeling. The effect of the potential interaction on the stabilizing function of Arid5a on the 3’UTR of target mRNAs was tested using a luciferase assay.
- F1EK293T cells were transfected with luciferase pGL-3 and empty pcDNA3.1 plasmids (Control), or pGL-3 plasmid encoding the 3’UTR of OX40, Il6 or Stat3, together with Arid5a-expressing pcDNA3.1 plasmid.
- the cells were treated with DMSO (Control and Arid5a) or POE (10-60 mM) dissolved in DMSO.
- Renilla-expressing plasmid was used as a control. Luciferase activity from cell lysates is shown relative to Control in Figs. 1A-1C.
- the graphs depicted in Figs. 1A-1C demonstrate that the Arid5a inhibitor POE inhibits Arid5a stabilizing function on the 3’UTR of OX40, Il6, and Stat3 mRNAs in a dose-dependent manner.
- the Arid5a inhibitor POE was further predicted by in silico modeling to interact with Arid5a, specifically through Pocket X, a feature of the Arid5a protein including but not limited to amino acids Glu53, Phe56, Leu57, VaI58, Leu84, Tyr88, Leul33, VaI134, Tyrl37, VaI138, Hisl40, and Leul41.
- the primary sequence of Arid5a (NP_001165676.1) was acquired from Ensemble and the 590 amino acid variant ENSMUST00000115032.7 was selected.
- the 3D coordinate of Arid5a was built to include residues 50-149 (SEQ ID NO: 1) of Arid5a.
- the binding sites of the target protein were identified using Q-site Finder and Pocket finder, and the binding domain (Pocket X) was chosen based on highest druggability score.
- Molecular docking simulation was carried out using SYBYLX 2.1 software (Tripos Associates Inc.) and Autodock 1.5.4 and 4.2 (Scripps Research). The candidate inhibitors were sorted based on predicted binding energy or CHEMPLP score.
- HEK293T cells were transfected with luciferase pGL-3 and empty pcDNA3.1 plasmids (Control), or pGL-3 plasmid encoding the 3’UTR of OX40, Il6 or Stat3, together with Arid5a-expressing pcDNA3.1 plasmid. Substitution mutations were introduced to the wild-type (WT) Arid5a at Phe56, Leu84, VaI134 and Tyrl37. Single point mutations were used to substitute Phe56 (TTC) with Cys (TGC) and VaI134 (GTC) with A1a (GCC).
- substitution mutations at Phe56, Leu84, VaI134 and Tyrl37 of Pocket X abolish the inhibitory effects of POE (40 mM) on the stabilizing function of Arid5a on OX40 3’UTR.
- substitution mutations at Phe56, Leu84, VaI134 and Tyrl37 of Pocket X abolish the inhibitory effects of POE (40 mM) on the stabilizing function of Arid5a on Il63’UTR.
- substitution mutations at Phe56, Leu84, Vall34 and Tyrl37 of Pocket X abolish the inhibitory effects of POE (40 mM) on the stabilizing function of Arid5a on Stat3 3’UTR.
- the anti-inflammatory activity of the Arid5a inhibitor POE was tested in vitro by measuring secretion of pro-inflammatory cytokines by macrophages and differentiated Th17 cells. Briefly, peritoneal macrophages were stimulated with LPS (0.5 ⁇ g/mL) for 24 h in presence or absence of POE (40 mM). Naive (CD4 + CD62L + ) T cells from the spleen were differentiated under Th17-polarizing conditions for 72 h in presence or absence of POE (40 pM). Levels of IL-6 and TNF- ⁇ were quantified in supernatant of macrophage culture; the results are shown in Figs. 3A and 3B.
- IL-17 was quantified in supernatant of polarized Th17 cell culture; the results are shown in Fig. 3C.
- the percentage of CD4 + OX40 + T cells in the polarized Th17 cells was determined using flow cytometry; the results are shown in Fig. 3D.
- Stat3 mRNA expression in the polarized Th17 cells was quantified by real-time PCR and normalized to Gapdh mRNA; the results are shown relative to those of untreated Th17 cells in Fig. 3E.
- POE reduces the level of IL-6 in cell culture supernatant of LPS-stimulated macrophages compared to LPS alone.
- POE does not affect the level of TNF- ⁇ in cell culture supernatant of LPS-stimulated macrophages compared to LPS alone.
- POE reduces the level of IL-17 in cell culture supernatant of polarized Th17 cells compared to untreated Th17 cells.
- POE reduces the frequency of CD4 + OX40 + T cells in polarized Th17 cells compared to untreated Th17 cells.
- POE reduces the expression of Stat3 mRNA in polarized Th17 cells compared to untreated Th17 cells.
- RNA-protein binding assay was performed to confirm that POE inhibits the physical binding of Arid5a to the (ADE)-like stem loop in the OX40 3’UTR.
- a 3'- biotinylated OX40 ADE-like stem loop (RNA; 5’-UCCACACCGUUCUAGGUGCUGG-3’) (SEQ ID NO: 2) was conjugated to streptavidin beads.
- the OX40 ADE-like stem loop/streptavidin bead conjugate was then mixed with Flag-Arid5a-enriched HEK293T cell lysate, washed, and proteins bound to RNA were eluted for immunoblot.
- Anti-Flag antibodies were used to detect Flag-Arid5a in the eluate by SDS-PAGE analysis. As shown in Fig. 4, POE inhibited the physical binding of Arid5a to OX40 ADE-like stem loop in a concentration- dependent manner.
- EAE was induced in C57BL/6 female mice using MOG35-55 (200 ⁇ g) emulsified in complete Freund’s adjuvant containing 10 mg/mL heat-killed Mycobacterium tuberculosis H37Ra.
- Mice received two intraperitoneal injections of pertussis toxin (500 ng) on days 0 and 2.
- the mice received one intraperitoneal injection of POE (0.5 mg) or corn oil per day starting from day 0 for four consecutive days. Serum levels of IL-6 and TNF- ⁇ were quantified on day 24.
- Encephalitogenic CD4 + T cells were isolated from lymph nodes of EAE mice and re-stimulated with MOG35-55 (30 ⁇ g/mL) and IL-23 (23 ng/mL) for 72 h; thereafter IL-7 was quantified in cell culture supernatant by ELISA.
- OX40 mRNA and protein were quantified in CD4 + T cells isolated from the CNS of EAE mice 10 days after disease induction. The mRNA was quantified by real-time PCR, normalized to Gapdh mRNA and presented relative to that of corn oil-treated EAE mice. The percentage of CD4 + /OX40 + T cells was analyzed using flow cytometry.
- POE treatment reduces EAE clinical scores compared to corn oil-treated mice (EAE).
- EAE corn oil-treated mice
- Fig. 5B POE reduces serum levels of IL-6 and TNF- ⁇ compared to corn oil-treated mice (EAE).
- Fig. 5C POE reduces the level of IL-17 in culture supernatant of encephalitogenic CD4 + T cells in response to restimulation compared to corn oil-treated mice (EAE).
- POE reduces the expression of OX40 mRNA in CD4 + T cells isolated from the CNS of EAE mice.
- Fig. 5E POE reduces the frequency of CD4 + OX40 + T cells in the CNS of EAE mice.
- Arid5a inhibitors identified in silico include but are not limited to POE analogs POE A1 (2- [5-methyl-1,3,4-oxadiazol-2-yl)sulfanyl]-1-phenylethan-1-one), POE A2 (2-[(5-methyl- l,3,4-thiadiazol-2-yl)amino]-1-phenylethan-1-one), POE A3 (2-Propanone, l-[[5-(3- pyridinyl)-1,3,4-oxadiazol-2-yl]thio]-).
- the compounds POE A1-A3 were selected as representative illustrative examples for further studies.
- the potential binding between POE analogs A1-A3 and Arid5a was predicted to be relatively strong, including a number of hydrogen bonds and pi interactions with respective binding energies of -6.16, -6.18 and, - 6.76, and -6.03, respectively .
- HEK293 T cells were transfected (Lipofectamine LTX; Invitrogen) with luciferase pGL-3 and empty pcDNA 3.1 plasmids (Control), or pGL-3 plasmid encoding the 3’UTR of IL6 together with Arid5a-expressing pcDNA3.1 plasmid. Renila-expressing plasmid was used as a Control.
- the cells were treated with DMSO (Control and Arid5a) or POE or its analogs A1-3 (40 mM; Aurora) dissolved in DMSO.
- the mouse Arid5a (NP_001165676.1) cDNA (WT; ENSMUST00000115032.7) was cloned in a Flag-tagged pcDNA3.1 plasmid at Xbal and EcoRl.
- Arid5a inhibitors interact with the target domain of Arid5a (Pocket X)
- substitution mutations were introduced to the wild-type (WT) Arid5a at Phe56, Tyrl37 and His 140 to produce mutant Arid5a (mArid5a). Mutations were introduced to substitute Phe56 with Cys, Tyrl37 with A1a, and Hisl40 with A1a.
- Luciferase activity from cell lysates was quantified using a Dual Luciferase kit (Promega) and the results were shown relative to the Control.
- CFA complete Freund adjuvant
- mice received one interperitoneal injection of corn oil (vehicle) or POE, POE A1, or POE A2 (0.25 mg). Serum levels of IL-6 were quantified on day 45 after first immunization using ELISA (Invitrogen), following manufacturer’s instructions.
- Flow cytometry analysis was conducted on CD4 + T cells isolated from secondary lymphoid organs on day 45 after first immunization using a MACS isolation kit (Miltenyi). The cells were stimulated with 50 ng/ml phorbol 12-myristate 13-acetate (Sigma-Aldrich) and 800 ng/ml ionomycin (Sigma-Aldrich) for 4 hours, and Protein Transport Inhibitor (Invitrogen) was added for the last two hours. PerCP-Cy5.5-conjugated anti-CD4 antibodies (eBioscience) were used for surface staining. An Intracellular Staining Kit (Life Technologies) and PE-conjugated anti-IL-17 antibodies (eBioscience) were used. Analysis was carried out using a FlowSight system (Amnis).
- parenteral treatment with POE or its example analogs POE A1 and POE A2 comparably reduced CIA clinical scores compared to corn oil-treated mice (CIA).
- POE or its analogs POE A1 and POE A2 reduced serum levels of IL-6 compared to CIA mice.
- POE or its analogs POE A1 and POE A2 reduced the frequency of CD4 + IL-17 + cells in the secondary lymphoid organs compared to CIA mice (Fig. 7C).
- Treatment ointment was prepared by mixing 1 mg of DMSO-dissolved POE or its representative analogs including POE A2 or POE A3 with 20 gm of Vaseline Petroleum Jelly Original (vehicle, Unilever Inc.); the mixture was then incubated at room temperature overnight. From day 0 to day 8 the mice were treated topically with the treatment ointment (40 mg/cm 2 ) or Vaseline (IMQ/control).
- the mRNAs encoding Il6 and III 7a were isolated from whole biopsies of the ear (day 8) and reverse transcribed to make cDNA.
- the cDNA was then amplified by real-time PCR using TaqMan Gene Expression Assays (Mm00446190_ml, Mm00439618_ml, respectively; Applied Biosystems).
- the relative expression of mRNAs was calculated by the AACt method and presented relative to that of IMQ control mice.
- topical treatment with POE or its example analogs POE A2 and POE A3 comparably reduced clinical scores (erythema and thickness of the right ear) of IMQ-induced psoriasis compared to Vaseline-treated mice (IMQ). Furthermore, POE or its analogs POE A2 and POE A3 suppressed mRNA expression of the pro-inflammatory cytokines Il6 and II17a in the whole biopsies of the right ear (Fig. 8B).
- POE and its analogs POE A1-A3 suppressed proliferation of LNCaP cells with an average of 61%.
- POE and its analogs POE A1-A3 (20 mM) suppressed proliferation of A549 cells with an average of 59%.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A method for treating and preventing autoimmune diseases and cancer can include administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising an Arid5a inhibitor and a pharmaceutically acceptable carrier. A screening method can include identifying candidate Arid5a inhibitors through in silico predicted binding to Arid5a target domains (Pocket X) and confirming AridSa inhibition through in vitro by binding and luciferase assays.
Description
THERAPEUTIC AGENTS FOR TREATING AND PREVENTING AUTOIMMUNE DISEASES AND CANCER AND A SCREENING METHOD
INCORPORATION BY REFERENCE OF MATERIAL SUBMITTED IN COMPUTER READABLE FORM
The Applicants hereby incorporate by reference the sequence listing contained in the ASCII text file titled 32087_15_sequence_Iisting_ST25.txt, created December 5, 2018 and having 1.23 KB of data.
TECHNICAL FIELD
The disclosure of the present patent application relates to RNA-binding protein (RBP) inhibitors, and particularly, to Arid5a inhibitors, methods of screening for Arid5a inhibitors, and methods of treating autoimmune diseases and cancer using an Arid5a inhibitor.
BACKGROUND ART
Inflammation, a body response to an injury, is divided into acute and chronic inflammation, wherein the chronic inflammation is a long-lasting event usually over months and years. Autoimmune diseases are chronic inflammatory diseases caused when a subject’s own immune system attacks otherwise healthy cells in the body. Common autoimmune diseases include multiple sclerosis (MS), rheumatoid arthritis (RA), psoriasis, inflammatory bowel disease (IBD), lupus, type 1 diabetes, Graves’ disease, and Guillan-Barre syndrome. Common symptoms of autoimmune diseases include fatigue, joint pain and swelling, skin problems, abdominal pain or digestive issues, recurring fever, swollen glands, and metabolic issues. Current treatments for autoimmune diseases are focused on alleviating symptoms and include primarily non-steroidal anti-inflammatory drugs (NSAIDs) and drugs intended to suppress the immune response. The NSAIDS treatments, as immune suppressants, are both limited in their impact and have significant harmful side effects.
Regardless of the site of inflammation associated with the autoimmune disease (for example, neuron in MS, joints in RA and the skin in psoriasis), they all share several pathophysiological features. The primary drivers of these features are pro-inflammatory cytokines and mediators. MS, as a representative of autoimmune diseases, involves both the innate and adaptive immune responses.
Innate immune cells, such as macrophages, contribute to pathogenesis of MS by secretion of pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis
factor-α (TNF-α). In addition, the antigen-presenting cells (APCs) of the innate immune response provide cytokine milieus that direct differentiation of naive CD4+ T cells into effector cells. These differentiated cells, mainly IL-17-secreting T helper 17 (Th17) cells are implicated in MS pathogenesis. Therefore, reducing any or all of the above mentioned pro- inflammatory cytokines, which are greatly implicated in autoimmune inflammation, has been an area of active investigation to develop a therapeutic strategy to treat MS.
Common treatments for MS and other autoimmune diseases typically focus on reducing exacerbations and disease progression rather than offering a cure. These treatments are classified as disease-modifying treatments (DMT). For example, interferon-β (IFN-β) has been used as an efficient DMT in MS patients. Flowever, this treatment is associated with increased levels of liver enzymes and flu-like symptoms. Other therapeutic agents such as mitoxantrone and humanized antibodies including daclizumab, natalizumab and alemtuzumab exert promising therapeutic effects in MS patients. Flowever, recent studies have shown that such treatments have severe side effects. Mitoxantrone is associated with cardiotoxicity and acute leukemia, alemtuzumab is associated with autoimmune-associated complications, and natalizumab is associated with progressive multifocal leukoencephalopathy.
Cancer is a disease caused by dysregulation of the cell division cycle, resulting in an uncontrolled growth of cells. Cancers are categorized based upon the cell type from which the cancer originated. Common cancers include breast cancer, prostate cancer, basal cell cancer, melanoma, colon cancer, lung cancer, leukemia, and lymphoma. Generally, cancer treatments focus on killing rapidly dividing cells. Common treatments include radiation therapies and chemotherapies. More recent treatments have been able to target some specific types of cancer cells. Flowever, most cancer treatments have significant side effects and are not always well tolerated.
Thus, alternative therapeutic agents for treating and preventing autoimmune diseases and cancer and screening methods for agents solving the aforementioned problems are desired.
DISCLOSURE OF INVENTION
Therapeutic agents for treating and preventing autoimmune diseases and cancer can include compositions comprising an AT-rich interactive domain containing 5 a (Arid5a) inhibitor. The autoimmune diseases can include diseases associated with chronic
inflammation. The autoimmune diseases can include but are not limited to, multiple sclerosis, rheumatoid arthritis, and psoriasis. The cancer may include but is not limited to, breast cancer, prostate cancer, and lung cancer. The Arid5a inhibitor can inhibit the RNA-binding activities of Arid5a and the subsequent stabilizing functions on target mRNAs encoding pro- inflammatory mediators. The Arid5a inhibitor can include 1-Phenyl-2-(5-pyridin-4-yl- [1,3,4]oxadiazol-2-ylsulfanyl)-ethanone (herein, “POE”), having a chemical structure according to the formula:
or a pharmaceutically acceptable salt thereof. It should be understood that the Arid5a inhibitor POE includes analogs of POE having any dihedral angles.
In an embodiment, the Arid5a inhibitors may include POE analogs having a chemical structure according to the following general formula:
wherein each of R1 and R2 is independently selected from H, alkyl, phenyl, substituted phenyl, a 5-membered heteroaryl, and 6-membered heteroaryl; each of X and Y is independently selected from S, O, and NH; and n is an integer representing a number of Cs selected from 0, 1, and 2. Preferably, n is 1.
POE A1.
In an embodiment, the POE analog is
It should be understood that POE analogs POE A1, POE A2 and POE A3 are shown for illustrations purposes only, and the Arid5a inhibitors include POE analogs having the chemical structure according to the general formula.
In a further embodiment, a method for treating and preventing autoimmune diseases and cancer can include administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising one or more (Arid5a) inhibitors alone or combined with other therapeutic or prophylactic agents.
These and other features of the present disclosure will become readily apparent upon further review of the following specification and drawings. BRIEF DESCRIPTION OF DRAWINGS
Fig. 1A depicts a graph of the effects of POE on Arid5a-mediated stability of the OX403’UTR.
Fig. IB depicts a graph of the effects of POE on Arid5a- mediated stability of the Il63’UTR. Fig. 1C depicts a graph of the effects of POE on Arid5a- mediated stability of the
Stat33’UTR.
Fig. 2A depicts a graph of the effect of substitution mutations in Arid5a on POE- mediated inhibition of Arid5a stabilizing function on the OX403’UTR.
Fig. 2B depicts a graph of the effect of substitution mutations in Arid5a on POE- mediated inhibition of Arid5a stabilizing function on the Il63’UTR.
Fig. 2C depicts a graph of the effect of substitution mutations in Arid5a on POE- mediated inhibition of Arid5a stabilizing function on the Stat33’UTR.
Fig. 3A depicts a graph of the effects of POE on IL-6 production by macrophages.
Fig. 3B depicts a graph of the effects of POE on TNF-α production by macrophages.
Fig. 3C depicts a graph of the effects of POE on IL-17 production by differentiated Th17 cells.
Fig. 3D depicts a graph of the effects of POE on CD4+OX40+ T cells in differentiated Th17 cells.
Fig. 3E depicts a graph of the effect of POE on Stat3 mRNA expression in differentiated Th17 cells.
Fig. 4 depicts the effect of POE on Arid5a binding to the alternative decay element (ADE)-like stem loop in the OX403'UTR.
Fig. 5A depicts a graph of EAE score over time with and without POE treatment.
Fig. 5B depicts a graph of IL-6 and TNF-α serum levels in the EAE model with and without treatment with POE.
Fig. 5C depicts a graph of IL-17 production by encephalitogenic CD4+ T cells in response to restimulation in the EAE model with and without treatment with POE.
Fig. 5D depicts a graph of OX40 mRNA levels in CD4+ T cells isolated from the CNS in the EAE model with and without treatment with POE.
Fig. 5E depicts a graph of percentage of CD4+OX40+ T cells isolated from the CNS in EAE model with and without treatment with POE.
Fig. 6 depicts a graph of the efficient inhibitory effects of POE and its example analogs POE A1-A3 on Arid5a stabilizing function on Il63’UTR through the target domain of Arid5a.
Fig. 7A depicts a graph of CIA clinical score over time with and without treatment with POE or its example analogs POE A1 or POE A2.
Fig. 7B depicts a graph of IL-6 serum level in the CIA model with and without treatment with POE or its example analogs POE A1 or POE A2.
Fig. 7C depicts a graph of the percentage of CD4+IL-17+ T cells in secondary lymphoid organs in the CIA model with and without treatment using POE or its example analogs POE A1 or POE A2.
Fig. 8A depicts a graph of the score of IMQ-induced-psoriasis model over time with and without treatment with POE or its example analogs POE A2 or POE A3.
Fig. 8B depicts a graph of mRNA expression of Il6 and II17a in a biopsy from IMQ-induced-psoriasis model with and without treatment with POE or its example analogs POE A2 or POE A3.
Fig. 9A depicts a graph of the anti-proliferative effects of POE and its example analogs POE A1-A3 on MDA-MB-231 breast cancer cells.
Fig. 9B depicts a graph of the anti-proliferative effects of POE and its example analogs POE A1-A3 on LNCaP prostate cancer cells.
Fig. 9C depicts a graph of the anti-proliferative effects of POE and its example analogs POE A1-A3 on A549 lung cancer cells.
Similar reference characters denote corresponding features consistently throughout the attached drawings.
BEST MODES OF CARRYING OUT THE INVENTION
As used herein, a “subject” includes mammals, e.g., humans, dogs, cats, sheep, cows, rats, mice, and the like.
As used herein, “Arid5a” refers to AT -rich interactive domain-containing 5a (Arid5A), a protein that stabilizes mRNAs encoding pro-inflammatory mediators, including signal transducer and activator of transcription 3 ( Stat3 ), Il6, and OX40 (CD 134).
As used herein, “effective amount” refers to an amount which provides a therapeutic or prophylactic benefit.
According to an embodiment, therapeutic agents for treating and preventing autoimmune diseases and cancer can include compositions comprising an AT-rich interactive domain containing 5a (Arid5a) inhibitor. The autoimmune diseases can include diseases associated with chronic inflammation. The autoimmune diseases can include but are not limited to, multiple sclerosis, rheumatoid arthritis, and psoriasis. The cancer may include but is not limited to, breast cancer, prostate cancer, and lung cancer. The Arid5a inhibitor can inhibit the RNA-binding activities of Arid5a and the subsequent stabilizing functions on target mRNAs encoding pro-inflammatory mediators. The Arid5a inhibitor can include 1-
Phenyl -2-(5-pyridin-4-yl-[ 1 ,3,4]oxadiazol-2-ylsulfanyl)-ethanone (herein, “POE”), having a chemical structure according to the formula:
or a pharmaceutically acceptable salt thereof. It should be understood that the Arid5a inhibitor POE includes analogs of POE having any dihedral angles.
In an embodiment, the Arid5a inhibitors include POE analogs having a chemical structure according to the following general formula:
wherein each of R1 and R2 is independently selected from H, alkyl, phenyl, substituted phenyl, a 5-membered heteroaryl, and 6-membered heteroaryl; each of X and Y is independently selected from S, O, and NH; and n is an integer representing a number of Cs selected from 0, 1, and 2. Preferably, n is 1.
In a further embodiment, a method for treating and preventing autoimmune diseases and cancer can include administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising one or more (Arid5a) inhibitors alone or combined with other therapeutic or prophylactic agents.
Arid5a is required for pathogenesis of experimental autoimmune encephalomyelitis (EAE), a murine model of MS, by stabilizing the mRNAs of Il6 and OX40. Arid5a is also required for autoimmunity through promoting differentiation and effector functions of Th17 cells by stabilizing Stat3 and OX40 mRNAs. Accordingly, the Arid5a inhibitor can be administered to a subject to treat autoimmune diseases, including but not limited to MS, RA, and Psoriasis.
In a further embodiment, the Arid5a inhibitor can be used to prevent the proliferation of cancer cells. Arid5a inhibitors are herein shown to inhibit proliferation of a broad spectrum of cancer cells including breast cancer cells, lung cancer cells, and prostate cancer cells. Accordingly, in an embodiment the Arid5a inhibitor may be administered to a
subject in need thereof to prevent the proliferation of cancer cells. In a further embodiment, the cancer cells, including but not limited to breast cancer cells, lung cancer cells, or prostate cancer cells.
An embodiment of the present subject matter is directed to a pharmaceutical composition comprising the Arid5a inhibitor compound and a pharmaceutically acceptable carrier. In an embodiment, the pharmaceutical composition includes the Arid5a inhibitor compound in combination with at least one of a therapeutic agent and a prophylactic agent.
An embodiment of the present subject matter is directed to a method of making the pharmaceutical composition including mixing the Arid5a inhibitor with a pharmaceutically acceptable carrier. For example, the method of making the pharmaceutical composition can include mixing the Arid5a inhibitor under sterile conditions with a pharmaceutically acceptable carrier and preservatives, buffers, or propellants to create the pharmaceutical composition; and presenting the pharmaceutical composition in a form suitable for daily, weekly, monthly, or life-long administration.
An embodiment of the present subject matter is directed to an analog or derivative of the Arid5a inhibitors described herein. In one embodiment, the Arid5a inhibitors described herein are candidates for derivatization. Thus, analogs of the Arid5a inhibitors described herein that have modulated potency, selectivity, and solubility are included herein and provide useful leads for drug discovery and drug development. In certain instances, during optimization new analogs are designed considering issues of drug delivery, metabolism, novelty, and safety.
In an embodiment, the composition of the present subject matter may be administered orally, nasally, rectally, parenterally, intracisternally, intra vaginally, intraperitoneally, topically, transdermally, by surgical implantation, or by intravenous or intramuscular injections. In an embodiment, the composition of the present subject matter is administered in a form selected from liquid oral preparations, solid oral preparations, parenteral preparations, injectable suspensions, and liposomes.
The Arid5a inhibitors or pharmaceutical compositions can be administered to a subject by any suitable route. For example, the compositions can be administered orally (including bucally and sublingually), nasally, rectally, intracisternally, intra vaginally, intraperitoneally, topically, transdermally (as by powders, ointments, or drops), parenterally, and/or by surgical implantation. As used herein, “parenteral” administration refers to modes of administration other than through the gastrointestinal tract, which include intravenous, intramuscular, intraperitoneal, intrasternal, intramammary, intraocular, retrobulbar,
intrapulmonary, intrathecal, subcutaneous and intraarticular injection and infusion. Surgical implantation may also be contemplated, including, for example, embedding the composition in the body such as, for example, in a tissue, in the abdominal cavity, under the splenic capsule, brain, or in the cornea.
Accordingly, the route of administration can include intranasal administration, oral administration, inhalation administration, subcutaneous administration, transdermal administration, intradermal administration, intra-arterial administration with or without occlusion, intracranial administration, intraventricular administration, intravenous administration, buccal administration, intraperitoneal administration, intraocular administration, intramuscular administration, implantation administration, topical administration, intratumor administration, and/or central venous administration.
To prepare the pharmaceutical composition, the Arid5a inhibitors or a salt thereof, as the active ingredient, is intimately admixed with a pharmaceutically acceptable carrier according to conventional pharmaceutical compounding techniques. Carriers are inert pharmaceutical excipients, including, but not limited to, binders, suspending agents, lubricants, flavorings, sweeteners, preservatives, dyes, and coatings. In preparing compositions in oral dosage form, any of the pharmaceutical carriers known in the art may be employed. For example, for liquid oral preparations, suitable carriers and additives include water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, and the like. Further, for solid oral preparations, suitable carriers and additives include starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like.
For parenteral use, the carrier will usually comprise sterile water, though other ingredients, for example, for purposes such as aiding solubility or for preservation, may be included. Injectable suspensions may also be prepared, in which case appropriate liquid carriers, suspending agents, and the like may be employed. Accordingly, the pharmaceutically acceptable carrier can include alcohol, dimethyl sulfoxide (DMSO), a physiological saline, a lipid based formulation, a liposomal formulation, a nanoparticle formulation, a micellar formulation, a water soluble formulation, a biodegradable polymer, an aqueous preparation, a hydrophobic preparation, a lipid based vehicle, or a polymer formulation.
The Arid5a inhibitors of the present disclosure also can be administered in the form of liposomes. Liposomes generally are derived from phospholipids or other lipid substances and are formed by mono- or multi-lamellar hydrated liquid crystals dispersed in an aqueous medium. Any nontoxic, physiologically acceptable and metabolizable lipid
capable of forming liposomes can be used. The present compositions in liposome form can include, in addition to a compound of the present disclosure, stabilizers, preservatives, excipients, and the like. The preferred lipids are the phospholipids and the phosphatidyl cholines (lecithins), both natural and synthetic.
Pharmaceutical compositions for parenteral injection can include pharmaceutically acceptable sterile aqueous or non-aqueous solutions, dispersions, suspensions, or emulsions, as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to use. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents, or vehicles include water ethanol, polyols (such as, glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils (such, as olive oil), and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
The present compositions can include adjuvants such as preservatives, wetting agents, emulsifying agents, and dispersing agents. Prevention of the action of microorganisms can be ensured by the inclusion of various anti-bacterial and anti-fungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It also may be desirable to include isotonic agents such as sugars, sodium chloride, and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the inclusion of agents which delay absorption, such as aluminum monostearate and gelatin. In some cases, in order to prolong the effect of the drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This result can be accomplished by the use of a liquid suspension of crystalline or amorphous materials with poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterahy administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.
The present compositions can be in unit dosage forms such as tablets, pills, capsules, powders, granules, ointments, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampules, auto-injector devices or suppositories, for oral parenteral, intranasal, sublingual or rectal administration, or for administration by inhalation or insufflation. The active compound can be mixed under sterile conditions with a pharmaceutically acceptable carrier and, if required, any needed preservatives, buffers, or
propellants. The composition can be presented in a form suitable for daily, weekly, monthly, or life-long administration. The pharmaceutical compositions herein will contain, per dosage unit, e.g., tablet, capsule, powder, injection, teaspoonful, suppository and the like, an amount of the active ingredient necessary to deliver an effective dose. A therapeutically effective amount of the Arid5a inhibitor or an amount effective to treat an autoimmune disease or cancer, may be determined initially from the Examples described herein and adjusted for a specific desired Arid5a inhibitor using routine methods. In an embodiment, a therapeutically effective amount is an amount sufficient to achieve the desired therapeutic effects, e.g., a concentration of Arid5a inhibitor in plasma that ranges from about 1 nM to about 25 uM.
In an embodiment, the present subject matter includes a method of identifying candidate Arid5a inhibitors. An in silico analysis may be conducted to screen for candidate inhibitors. For example, molecular docking simulations can be used for screening a candidate inhibitor useful for treating autoimmune diseases and cancer. Candidate Arid5a inhibitors may be selected based on predicted interactions with a target domain in Arid5a. The target domain may be Pocket X, a feature of the Arid5a protein including, but not limited to, amino acids Glu53, Phe56, Leu57, VaI58, Leu84, Tyr88, Leul33, VaI134, Tyrl37, VaI138, Hisl40, and Leul41. Candidate Arid5a inhibitors are then tested in vitro by examining the candidate inhibitors’ effects on the stabilizing function of Arid5a on target mRNAs encoding pro- inflammatory mediators using a luciferase assay. The mRNAs can be of OX40, Il6, and Stat3. Candidate Arid5a inhibitors are then tested in vitro by examining the candidate inhibitors’ effects on Arid5a binding activities to stem loops in the 3’UTR of target mRNAs and production of pro-inflammatory mediators using a RNA-protein binding system, PCR, and ELISA tests. Finally, the therapeutic potential of candidate Arid5a inhibitors may be assessed in vivo using commonly used representative experimental autoimmune models including MS, RA and psoriasis. A therapeutic potential can be determined according to clinical scores, cytokine levels, changes in CD4+ T cell population, and OX40 expression.
The following examples illustrate the present teachings.
Example 1
Experimental Conditions
Experiments described herein were conducted using the following general experimental conditions.
Female C57BL/6 mice (6-8 weeks) were purchased originally from Charles River and maintained under specific pathogen-free conditions. All in vivo and in vitro animal
experiments were performed using these mice at Laboratory of Physiology and Immunology, King Faisal University, Saudi Arabia, in accordance with institutional guidelines.
The peritoneal macrophages were stimulated in vitro with 0.5 μg/mL lipopolysaccharides (LPS) (Sigma- Aldrich) for 24 h. The CD4+CD62L+ T cells were isolated and purified from spleen using the MACS isolation kit (Miltenyi). The T cells were cultured in the presence of anti-CD3/CD28 dynabeads (Invitrogen), recombinant mouse IL-6 (30 ng/mL; R&D Systems), recombinant transforming growth factor-β (TGF-β) (4 ng/mL; R&D Systems), anti-interferon-γ (IFN-γ) and anti-IL-4 (10 μg/mL; Biolegend) for 72 h to generate Th17 cells.
The mRNAs and cytokines were quantified as follows. A first strand of cDNA was synthesized from total RNA by using the TaqMan reverse transcription kit. The cDNA was amplified in the real-time PCR system ViiA7 using TaqMan gene expression assays of OX40 (Mm01261022_ml), Stat3 (Mm01219775_ml) and the endogenous control Gapdh (Mm99999915_gl). Kits, probes and reagents were from Applied Biosystems. The relative expression of mRNAs was calculated by AACt method. For cytokines quantification in serum and cell culture supernatants, ELISA kits of IL-17a, IL-6, TNF-α (Invitrogen) were used following the manufacturer’s instructions.
Flow cytometry analysis was conducted using CD4+ T cells cultured under Th17 cell-inducing conditions or CD4+ T cells derived from CNS, which were fixed and stained with Per-CP-Cy5.5-conjugated anti-CD4 antibodies and PE-conjugated anti-OX40 antibodies (Biolegend). Analysis was carried out using Flowsight (Amnis).
Data are presented as mean ± SD from representative experiment studied in triplicates out of at least three independent experiments produced similar results. The statistical significance between means was tested by one-way ANOVA. Two-way ANOVA was used to analyze the statistical significance of the data obtained from EAE, RA, and psoriasis models’ clinical scores (* = p < 0.05).
Example 2
Luciferase Assay of POE Inhibitory Effects on Arid5a Functions
The potential interaction between Arid5a inhibitor POE and Arid5a was predicted by in silico modeling. The effect of the potential interaction on the stabilizing function of Arid5a on the 3’UTR of target mRNAs was tested using a luciferase assay.
Briefly, F1EK293T cells were transfected with luciferase pGL-3 and empty pcDNA3.1 plasmids (Control), or pGL-3 plasmid encoding the 3’UTR of OX40, Il6 or Stat3, together with Arid5a-expressing pcDNA3.1 plasmid. The cells were treated with DMSO
(Control and Arid5a) or POE (10-60 mM) dissolved in DMSO. The mouse Arid5a (NP_001165676.1) cDNA (WT; ENSMUST00000115032.7) was cloned in a Flag-tagged pcDNA3.1 plasmid at Xbal and Ecorl. Renilla-expressing plasmid was used as a control. Luciferase activity from cell lysates is shown relative to Control in Figs. 1A-1C. The graphs depicted in Figs. 1A-1C demonstrate that the Arid5a inhibitor POE inhibits Arid5a stabilizing function on the 3’UTR of OX40, Il6, and Stat3 mRNAs in a dose-dependent manner.
Example 3
Luciferase Assay of POE Inhibitory Effects on Pocket X-mutant Arid5a
The Arid5a inhibitor POE was further predicted by in silico modeling to interact with Arid5a, specifically through Pocket X, a feature of the Arid5a protein including but not limited to amino acids Glu53, Phe56, Leu57, VaI58, Leu84, Tyr88, Leul33, VaI134, Tyrl37, VaI138, Hisl40, and Leul41. The primary sequence of Arid5a (NP_001165676.1) was acquired from Ensemble and the 590 amino acid variant ENSMUST00000115032.7 was selected. The 3D coordinate of Arid5a was built to include residues 50-149 (SEQ ID NO: 1) of Arid5a. The binding sites of the target protein were identified using Q-site Finder and Pocket finder, and the binding domain (Pocket X) was chosen based on highest druggability score. Molecular docking simulation was carried out using SYBYLX 2.1 software (Tripos Associates Inc.) and Autodock 1.5.4 and 4.2 (Scripps Research). The candidate inhibitors were sorted based on predicted binding energy or CHEMPLP score.
The effect of the interaction between POE with specific residues in Pocket X on the stabilizing function of Arid5a on the 3’UTR of target mRNAs was confirmed by using a luciferase assay.
Briefly, HEK293T cells were transfected with luciferase pGL-3 and empty pcDNA3.1 plasmids (Control), or pGL-3 plasmid encoding the 3’UTR of OX40, Il6 or Stat3, together with Arid5a-expressing pcDNA3.1 plasmid. Substitution mutations were introduced to the wild-type (WT) Arid5a at Phe56, Leu84, VaI134 and Tyrl37. Single point mutations were used to substitute Phe56 (TTC) with Cys (TGC) and VaI134 (GTC) with A1a (GCC). Sequential point mutations were used to substitute Leu84 (CTG) with A1a (GCG) and Tyrl37 (TAT) with A1a (GCT). Luciferase activity from cell lysates is shown relative to Control in Figs. 2A-2C.
As shown in Fig. 2A, substitution mutations at Phe56, Leu84, VaI134 and Tyrl37 of Pocket X abolish the inhibitory effects of POE (40 mM) on the stabilizing function of Arid5a on OX40 3’UTR. As shown in Fig. 2B, substitution mutations at Phe56, Leu84, VaI134 and Tyrl37 of Pocket X abolish the inhibitory effects of POE (40 mM) on the
stabilizing function of Arid5a on Il63’UTR. As shown in Fig. 2C, substitution mutations at Phe56, Leu84, Vall34 and Tyrl37 of Pocket X abolish the inhibitory effects of POE (40 mM) on the stabilizing function of Arid5a on Stat3 3’UTR.
Example 4
Anti-Inflammatory Activity of POE
The anti-inflammatory activity of the Arid5a inhibitor POE was tested in vitro by measuring secretion of pro-inflammatory cytokines by macrophages and differentiated Th17 cells. Briefly, peritoneal macrophages were stimulated with LPS (0.5 μg/mL) for 24 h in presence or absence of POE (40 mM). Naive (CD4+CD62L+) T cells from the spleen were differentiated under Th17-polarizing conditions for 72 h in presence or absence of POE (40 pM). Levels of IL-6 and TNF-α were quantified in supernatant of macrophage culture; the results are shown in Figs. 3A and 3B. IL-17 was quantified in supernatant of polarized Th17 cell culture; the results are shown in Fig. 3C. The percentage of CD4+OX40+ T cells in the polarized Th17 cells was determined using flow cytometry; the results are shown in Fig. 3D. Stat3 mRNA expression in the polarized Th17 cells was quantified by real-time PCR and normalized to Gapdh mRNA; the results are shown relative to those of untreated Th17 cells in Fig. 3E.
As shown in Fig. 3A, POE reduces the level of IL-6 in cell culture supernatant of LPS-stimulated macrophages compared to LPS alone. As shown in Fig. 3B, POE does not affect the level of TNF-α in cell culture supernatant of LPS-stimulated macrophages compared to LPS alone. As shown in Fig. 3C, POE reduces the level of IL-17 in cell culture supernatant of polarized Th17 cells compared to untreated Th17 cells. As shown in Fig. 3D, POE reduces the frequency of CD4+OX40+ T cells in polarized Th17 cells compared to untreated Th17 cells. As shown in Fig. 3E, POE reduces the expression of Stat3 mRNA in polarized Th17 cells compared to untreated Th17 cells.
Example 5
RNA-Arid5a Binding Assay
An RNA-protein binding assay was performed to confirm that POE inhibits the physical binding of Arid5a to the (ADE)-like stem loop in the OX40 3’UTR. Briefly, a 3'- biotinylated OX40 ADE-like stem loop (RNA; 5’-UCCACACCGUUCUAGGUGCUGG-3’) (SEQ ID NO: 2) was conjugated to streptavidin beads. The OX40 ADE-like stem loop/streptavidin bead conjugate was then mixed with Flag-Arid5a-enriched HEK293T cell lysate, washed, and proteins bound to RNA were eluted for immunoblot. Anti-Flag antibodies were used to detect Flag-Arid5a in the eluate by SDS-PAGE analysis. As shown in Fig. 4,
POE inhibited the physical binding of Arid5a to OX40 ADE-like stem loop in a concentration- dependent manner.
Example 6
Therapeutic Effects of POE in Experimental Multiple Sclerosis
Briefly, EAE was induced in C57BL/6 female mice using MOG35-55 (200 μg) emulsified in complete Freund’s adjuvant containing 10 mg/mL heat-killed Mycobacterium tuberculosis H37Ra. Mice received two intraperitoneal injections of pertussis toxin (500 ng) on days 0 and 2. The mice received one intraperitoneal injection of POE (0.5 mg) or corn oil per day starting from day 0 for four consecutive days. Serum levels of IL-6 and TNF-α were quantified on day 24. Encephalitogenic CD4+ T cells were isolated from lymph nodes of EAE mice and re-stimulated with MOG35-55 (30 μg/mL) and IL-23 (23 ng/mL) for 72 h; thereafter IL-7 was quantified in cell culture supernatant by ELISA. OX40 mRNA and protein were quantified in CD4+ T cells isolated from the CNS of EAE mice 10 days after disease induction. The mRNA was quantified by real-time PCR, normalized to Gapdh mRNA and presented relative to that of corn oil-treated EAE mice. The percentage of CD4+/OX40+ T cells was analyzed using flow cytometry.
As shown in Fig. 5A, POE treatment reduces EAE clinical scores compared to corn oil-treated mice (EAE). As shown in Fig. 5B, POE reduces serum levels of IL-6 and TNF-α compared to corn oil-treated mice (EAE). As shown in Fig. 5C, POE reduces the level of IL-17 in culture supernatant of encephalitogenic CD4+ T cells in response to restimulation compared to corn oil-treated mice (EAE). As shown in Fig. 5D, POE reduces the expression of OX40 mRNA in CD4+ T cells isolated from the CNS of EAE mice. As shown in Fig. 5E, POE reduces the frequency of CD4+OX40+ T cells in the CNS of EAE mice.
Example 7 POE Analogs
Further molecular docking simulations were performed to look for potential binding between Arid5a and several POE analogs, and then define common characteristics for such analogs. These simulations identified a common structure of the POE analogs that would interact with Arid5a, comprising substituted oxa/thiadiazole and triazole compounds of the formula:
wherein each of R1 and R2 is independently selected from H, alkyl, phenyl, substituted phenyl, a 5-membered heteroaryl, and 6-membered heteroaryl; each of X and Y is independently selected from S, O, and NH; and n is an integer selected from 0, 1, and 2. Arid5a inhibitors identified in silico include but are not limited to POE analogs POE A1 (2- [5-methyl-1,3,4-oxadiazol-2-yl)sulfanyl]-1-phenylethan-1-one), POE A2 (2-[(5-methyl- l,3,4-thiadiazol-2-yl)amino]-1-phenylethan-1-one), POE A3 (2-Propanone, l-[[5-(3- pyridinyl)-1,3,4-oxadiazol-2-yl]thio]-). The compounds POE A1-A3 were selected as representative illustrative examples for further studies. The potential binding between POE analogs A1-A3 and Arid5a was predicted to be relatively strong, including a number of hydrogen bonds and pi interactions with respective binding energies of -6.16, -6.18 and, - 6.76, and -6.03, respectively .
Example 8
Luciferase Assay of POE Analogs Inhibitory Effects on Arid5a Functions
HEK293 T cells (ATCC) were transfected (Lipofectamine LTX; Invitrogen) with luciferase pGL-3 and empty pcDNA 3.1 plasmids (Control), or pGL-3 plasmid encoding the 3’UTR of IL6 together with Arid5a-expressing pcDNA3.1 plasmid. Renila-expressing plasmid was used as a Control. The cells were treated with DMSO (Control and Arid5a) or POE or its analogs A1-3 (40 mM; Aurora) dissolved in DMSO. The mouse Arid5a (NP_001165676.1) cDNA (WT; ENSMUST00000115032.7) was cloned in a Flag-tagged pcDNA3.1 plasmid at Xbal and EcoRl.
To examine whether the Arid5a inhibitors interact with the target domain of Arid5a (Pocket X), substitution mutations were introduced to the wild-type (WT) Arid5a at Phe56, Tyrl37 and His 140 to produce mutant Arid5a (mArid5a). Mutations were introduced to substitute Phe56 with Cys, Tyrl37 with A1a, and Hisl40 with A1a. Luciferase activity from cell lysates was quantified using a Dual Luciferase kit (Promega) and the results were shown relative to the Control.
As shown in Fig. 6, POE and its analogs A1-3 (40 pM) abolished the stabilizing function of Arid5a and shortened the half-life of Il63’UTR. These results confirm that the representative POE analogs POE A1-A3 are efficient Arid5a inhibitors. Further investigations showed that substitution mutations at Phe56, Tyrl37, and Hisl40 of the target domain of Arid5a abolish the inhibitor effects of the Arid5a inhibitors and reinstated Arid5a function (See Fig. 6). These results confirm that the interaction between the Arid5a inhibitors and the target domain of Arid5a (Pocket X) is required for the Arid5a inhibitors to inhibit Arid5a’s stabilizing function. Example 9
Therapeutic Effects of POE and POE Analogs in Experimental Rheumatoid Arthritis
Collagen-induced arthritis (CIA) was induced following a modified method described previously (Nakahama et al 2011). Briefly, chicken type II collagen (CII; Sigma
Aldrich) was dissolved in 10 mM acetic acid (4 mg/ml) at 4°C overnight. C57BL mice (n=5) were injected at the base of the tail with 100 μg CII emulsified in complete Freund adjuvant (CFA, F137Ra; Difco Laboratories). The same injection was repeated 14 days later. Evaluation of CIA was as follows: 0 = normal, 1 = edema or swelling, 2 = edema and erythema at foot or ankle, 3 = edema and erythema from ankle to the tarsal bone, 4 = edema at entire leg and joint distortion. On days 0, 3, 6, 9, 12, 15, and 18 after first immunization, the mice received one interperitoneal injection of corn oil (vehicle) or POE, POE A1, or POE A2 (0.25 mg). Serum levels of IL-6 were quantified on day 45 after first immunization using ELISA (Invitrogen), following manufacturer’s instructions.
Flow cytometry analysis was conducted on CD4+ T cells isolated from secondary lymphoid organs on day 45 after first immunization using a MACS isolation kit (Miltenyi). The cells were stimulated with 50 ng/ml phorbol 12-myristate 13-acetate (Sigma-Aldrich) and 800 ng/ml ionomycin (Sigma-Aldrich) for 4 hours, and Protein Transport Inhibitor (Invitrogen) was added for the last two hours. PerCP-Cy5.5-conjugated anti-CD4 antibodies (eBioscience) were used for surface staining. An Intracellular Staining Kit (Life Technologies) and PE-conjugated anti-IL-17 antibodies (eBioscience) were used. Analysis was carried out using a FlowSight system (Amnis).
As shown in Fig. 7A, parenteral treatment with POE or its example analogs POE A1 and POE A2 comparably reduced CIA clinical scores compared to corn oil-treated mice (CIA). As depicted in Fig. 7B, POE or its analogs POE A1 and POE A2 reduced serum levels of IL-6 compared to CIA mice. Furthermore, POE or its analogs POE A1 and POE A2 reduced the frequency of CD4+IL-17+ cells in the secondary lymphoid organs compared to CIA mice (Fig. 7C).
Example 10
Therapeutic Effects of POE and POE Analogs in Experimental Psoriasis
Experimental psoriasis was induced following a modified method described previously (Sun et al. 2013). To induce disease in male BALB/c mice (6-8 weeks; n=6), imiquimod (IMG; Sichuan Med-Shine Pharmaceutical) at 5% was applied topically at 20 mg/cm2 on the inside of the right ear for 8 consecutive days. An evaluation system for assessment of erythema and thickness of the ear was developed. Erythema was assessed using a table with red taints (0-4) and ear thickness (0-4) measured using a digital caliber on days 2, 4, 6, and 8 after first IMQ application. The sum of the two parameters scores (ranging from 0-8) was used to indicate the overall clinical score.
Treatment ointment was prepared by mixing 1 mg of DMSO-dissolved POE or its representative analogs including POE A2 or POE A3 with 20 gm of Vaseline Petroleum Jelly Original (vehicle, Unilever Inc.); the mixture was then incubated at room temperature overnight. From day 0 to day 8 the mice were treated topically with the treatment ointment (40 mg/cm2) or Vaseline (IMQ/control).
The mRNAs encoding Il6 and III 7a were isolated from whole biopsies of the ear (day 8) and reverse transcribed to make cDNA. The cDNA was then amplified by real-time PCR using TaqMan Gene Expression Assays (Mm00446190_ml, Mm00439618_ml, respectively; Applied Biosystems). The relative expression of mRNAs was calculated by the AACt method and presented relative to that of IMQ control mice.
As depicted in Fig. 8A, topical treatment with POE or its example analogs POE A2 and POE A3 comparably reduced clinical scores (erythema and thickness of the right ear) of IMQ-induced psoriasis compared to Vaseline-treated mice (IMQ). Furthermore, POE or its analogs POE A2 and POE A3 suppressed mRNA expression of the pro-inflammatory cytokines Il6 and II17a in the whole biopsies of the right ear (Fig. 8B).
Example 11 Cancer
Breast cancer cells of the cell line MDA-MB-231, prostate cancer cells of the cell line LNCaP, and lung cancer cells of the cell line A549 were obtained from ATCC. The cells were cultured in DMEM/F-12 medium containing 10% FBS and antibiotic antimycotic solution (Sigma- Aldrich). Cell Counting Kits (CCK-8; Dojindo) were used to perform proliferation assays. Briefly, cells of the various cell lines were seeded in 96-well plates for 48 hours with tetrazolium added for the last 4 hours. Color formation was quantified using a plate reader, and proliferation results in the presence of DMSO-dissolved POE or its example analogs POE A1-A3 were presented relative to DMSO-treated cells (control). All data are presented as cell viability (%).
Viability studies using MDA-MB-231, LNCaP, and A549 cells showed that the average half maximal inhibitory concentrations (IC50) of POE and its analogues POE A 1-3 were 27.8 mM (MD-MB-231), 34.6 pM (LNCaP), and 28.4 pM (A549). The anti- proliferative effects of POE and its example analogs POE A1-A3 on cancer cell lines are shown in Figs. 9A-9C. As shown in Fig. 9A, POE and its analogs POE A1-A3 (20 pM) suppressed viability of MDA-MB-231 cells with an average of 64%. As shown in Fig. 9B, POE and its analogs POE A1-A3 (25 pM) suppressed proliferation of LNCaP cells with an
average of 61%. As shown in Fig. 9C, POE and its analogs POE A1-A3 (20 mM) suppressed proliferation of A549 cells with an average of 59%.
It is to be understood that the therapeutic agents for treating and preventing autoimmune diseases and cancer and a screening method is not limited to the specific embodiments described above, but encompasses any and all embodiments within the scope of the generic language of the following claims enabled by the embodiments described herein, or otherwise shown in the drawings or described above in terms sufficient to enable one of ordinary skill in the art to make and use the claimed subject matter.
Claims
1. A method of treating and preventing a disease, comprising: administering to a subject in need thereof a therapeutically effective amount of an AridSa inhibitor, wherein the AridSa inhibitor comprises a compound having the formula:
or a pharmaceutically acceptable salt thereof, and the disease comprises at least one of an autoimmune disease and a cancer.
2. An AridSa inhibitor comprising a compound having a chemical structure according to the general formula:
wherein each of R1 and R2 is independently selected from the group consisting of H, alkyl, phenyl, substituted phenyl, a 5-membered heteroaryl, and a 6-membered heteroaryl; each of X and Y is independently selected from the group consisting of S, O, and NH; and n is an integer selected from 0, 1, and 2.
3. The Arid5a inhibitor of claim 2, wherein the AridSa inhibitor comprises a compound selected from the group consisting of:
4. A method of treating or preventing a disease, comprising administering to a subject in need thereof an effective amount of one or more Arid5a inhibitors of claim 2, wherein the disease comprises at least one of an autoimmune disease and a cancer.
5. The method of claim 4, wherein the AridSa inhibitor comprises a compound selected from the group consisting of:
6. The method of claim 4, wherein the autoimmune disease is a disease associated with chronic inflammation.
7. The method of claim 6, wherein the autoimmune disease is selected from the group consisting of multiple sclerosis, rheumatoid arthritis, and psoriasis.
8. The method of claim 4, wherein treating or preventing cancer comprises inhibition of cancer cell proliferation.
9. The method of claim 8, wherein the cancer cells are selected from the group consisting of breast cancer cells, prostate cancer cells, or lung cancer cells.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/920,584 US20200338058A1 (en) | 2019-04-28 | 2020-07-03 | Therapeutic agents for treating and preventing autoimmune diseases and cancer and a screening method |
US16/920,584 | 2020-07-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022003439A1 true WO2022003439A1 (en) | 2022-01-06 |
Family
ID=79315632
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2021/054450 WO2022003439A1 (en) | 2020-07-03 | 2021-05-21 | Therapeutic agents for treating and preventing autoimmune diseases and cancer and a screening method |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2022003439A1 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009078587A2 (en) * | 2007-12-14 | 2009-06-25 | Korea Research Institute Of Bioscience And Biotechnology | Composition for prevention and treatment of cancer containing triazolyl-thio-ethanone derivatives inhibiting activity of protein phosphatases or pharmaceutically acceptable salts thereof as an active ingredient |
US20090163545A1 (en) * | 2007-12-21 | 2009-06-25 | University Of Rochester | Method For Altering The Lifespan Of Eukaryotic Organisms |
WO2014165090A1 (en) * | 2013-03-13 | 2014-10-09 | The Broad Institute, Inc. | Compounds for the treatment of tuberculosis |
US10512639B1 (en) * | 2019-04-28 | 2019-12-24 | King Faisal University | Therapeutic agents for treating diseases associated with chronic inflammation and screening method |
-
2021
- 2021-05-21 WO PCT/IB2021/054450 patent/WO2022003439A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009078587A2 (en) * | 2007-12-14 | 2009-06-25 | Korea Research Institute Of Bioscience And Biotechnology | Composition for prevention and treatment of cancer containing triazolyl-thio-ethanone derivatives inhibiting activity of protein phosphatases or pharmaceutically acceptable salts thereof as an active ingredient |
US20090163545A1 (en) * | 2007-12-21 | 2009-06-25 | University Of Rochester | Method For Altering The Lifespan Of Eukaryotic Organisms |
WO2014165090A1 (en) * | 2013-03-13 | 2014-10-09 | The Broad Institute, Inc. | Compounds for the treatment of tuberculosis |
US10512639B1 (en) * | 2019-04-28 | 2019-12-24 | King Faisal University | Therapeutic agents for treating diseases associated with chronic inflammation and screening method |
Non-Patent Citations (1)
Title |
---|
MOCHONA, B. ET AL.: "Design and evaluation of novel oxadiazole derivatives as potential prostate cancer agents", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 26, 2016, pages 2847 - 2851, XP029557110, DOI: 10.1016/j.bmcl.2016.04.058 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10736910B2 (en) | Treatment of autophagy-based disorders and related pharmaceutical compositions, diagnostic and screening assays and kits | |
KR101819869B1 (en) | Boron-containing small molecules as anti-inflammatory agents | |
Ha et al. | Role of the CXCL8-CXCR1/2 axis in cancer and inflammatory diseases | |
US20220339169A1 (en) | Methods of treating or selecting a treatment for a subject resistant to tnf inhibitor using a nlrp3 antagonist | |
JP5969255B2 (en) | Treatment of inflammation-related diseases | |
ES2863996T3 (en) | Combination therapy for cancer treatment | |
EP2773360B1 (en) | Administration of nedd8-activating enzyme inhibitor and hypomethylating agent | |
CA2019974C (en) | Treatment of inflammation | |
US10709696B1 (en) | Therapeutic agents for treating diseases associated with chronic inflammation and screening method | |
KR100969634B1 (en) | A composition for treatment of atopic dermatitis comprising glucosamine and derivatives thereof and a method for treatment of atopic dermatitis using them | |
EP3681861A1 (en) | Cxcr-2 inhibitors for treating disorders | |
US11274132B2 (en) | Combined preparations of PKM2 modulators and HMGB1 | |
Jonsson et al. | Mycophenolic acid inhibits inosine 5′-monophosphate dehydrogenase and suppresses production of pro-inflammatory cytokines, nitric oxide, and LDH in macrophages | |
KR20200014790A (en) | Tinostamustine used to treat ovarian cancer | |
KR20180121571A (en) | Combination therapy with LIV1-ADC and chemotherapeutic agents | |
WO2021207598A1 (en) | Combination treatment with an agonist of p53 and a second therapeutic agent | |
Yu et al. | Two birds, one stone: hesperetin alleviates chemotherapy-induced diarrhea and potentiates tumor inhibition | |
CN111253327A (en) | Application of carboxyamidotriazole compound or salt thereof in preparation of medicines for treating NLRP3 inflammatory-body-activation-related diseases | |
US11654138B2 (en) | Therapeutic agents for treating and preventing autoimmune diseases and cancer and a screening method | |
WO2022003439A1 (en) | Therapeutic agents for treating and preventing autoimmune diseases and cancer and a screening method | |
US11773137B2 (en) | Arid5a peptide inhibitors | |
US20200170990A1 (en) | Method for treating schnitzler's syndrome | |
JP5198848B2 (en) | Treatment of type 1 diabetes using macrophage migration inhibitory factor inhibitor | |
US20050119197A1 (en) | Naadp analogues for modulating t-cell activity | |
Parker et al. | Ruxolitinib cream ameliorates spontaneous atopic dermatitis in the IL-33 transgenic mouse model |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21833662 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21833662 Country of ref document: EP Kind code of ref document: A1 |